Clinically, BCR-ABL tyrosine kinase inhibitors (TKIs) have achieved great treatment outcomes for Ph+ leukemias.6 However, some patients do not respond well or relapsed due to BCR-ABL mutation (e.g., T315I, G250E, Q252H, Y253H) associated TKI resistance7 and other unknown reasons.8 CML blast crisis (BC) can occur with disease progression due to the accumulation of additional oncogenic hits, genomic instability, epigenetic changes, or microenvironmental shifts. This evidence concerns the gene ABL1 and breast cancer.